Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8561101 | 0.81 | POLB (0.53) | POLBMEN1KMT2ANCOA1NCOA3 | |
| SCHEMBL28058588 | 0.79 | POLB (0.51) | POLBMEN1KMT2ANCOA1NCOA3 | |
| SCHEMBL15824026 | 0.79 | POLB (0.51) | POLBCTSBMEN1KMT2ANCOA1 | |
| SCHEMBL4727431 | 0.79 | POLB (0.51) | POLBMEN1KMT2ANCOA1NCOA3 | |
| SCHEMBL1033969 | 0.79 | POLB (0.51) | POLBCTSBMEN1KMT2ANCOA1 | |
| SCHEMBL202663 | 0.79 | POLB (0.51) | POLBMEN1KMT2ANCOA1NCOA3 | |
| SCHEMBL8570782 | 0.79 | POLB (0.51) | POLBCTSBMEN1KMT2ANCOA1 | |
| SCHEMBL29381779 | 0.79 | POLB (0.51) | POLBMEN1KMT2ANCOA1NCOA3 | |
| Hydrochloric Acid SCHEMBL3867195 | 0.78 | POLB (0.50) | POLBMEN1KMT2ANCOA1NCOA3 | |
| SCHEMBL31197366 | 0.78 | POLB (0.50) | POLBMEN1KMT2ANCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108003153-A | Nitrogenous five-ring heterocycles and quinolines and its salt, preparation method, pharmaceutical composition and purposes | 中国医学科学院肿瘤医院 | 2018-05-08 | — | — | CN | claimed |
| EP-4178676-B1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-02-03 | — | — | US | disclosed |
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-04-24 | — | — | US | disclosed |
| EP-4522615-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3759107-B1 | SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4448519-A1 | N-1 TRIAZOLE SUBSTITUTED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | Solventum Intellectual Properties Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-09-12 | — | — | US | disclosed |
| CN-118401523-A | N-1 triazole substituted imidazoquinolines, conjugates thereof and methods | 舒万诺知识产权公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1198232-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076518-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IRF3, IFNAR1, IFNG | POLB 1249/4885CTSB 3036/4885MEN1 2108/4885 |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | IFNG, IFNAR1, IRF3 | POLB 1634/4885CTSB 3011/4885MEN1 1417/4885 |
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | POLB 877/4885CTSB 1770/4885MEN1 1490/4885 |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | IFNG, IFNAR1, IL2 | POLB 2893/4885CTSB 2240/4885MEN1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.